DK1339409T3 - Anvendelse af rosuvastatin (ZD-4522) til behandling af heterozygot, familiær hypercholesterolæmi - Google Patents

Anvendelse af rosuvastatin (ZD-4522) til behandling af heterozygot, familiær hypercholesterolæmi

Info

Publication number
DK1339409T3
DK1339409T3 DK01982623T DK01982623T DK1339409T3 DK 1339409 T3 DK1339409 T3 DK 1339409T3 DK 01982623 T DK01982623 T DK 01982623T DK 01982623 T DK01982623 T DK 01982623T DK 1339409 T3 DK1339409 T3 DK 1339409T3
Authority
DK
Denmark
Prior art keywords
rosuvastatin
treatment
familial hypercholesterolemia
heterozygous familial
heterozygous
Prior art date
Application number
DK01982623T
Other languages
Danish (da)
English (en)
Inventor
Ali Raza
Howard Gerard Hutchinson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1339409(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1339409T3 publication Critical patent/DK1339409T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01982623T 2000-11-22 2001-11-16 Anvendelse af rosuvastatin (ZD-4522) til behandling af heterozygot, familiær hypercholesterolæmi DK1339409T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (1)

Publication Number Publication Date
DK1339409T3 true DK1339409T3 (da) 2008-09-08

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01982623T DK1339409T3 (da) 2000-11-22 2001-11-16 Anvendelse af rosuvastatin (ZD-4522) til behandling af heterozygot, familiær hypercholesterolæmi

Country Status (35)

Country Link
US (1) US6858618B2 (uk)
EP (1) EP1339409B1 (uk)
JP (2) JP5062940B2 (uk)
KR (1) KR100815042B1 (uk)
CN (1) CN1268339C (uk)
AR (1) AR031766A1 (uk)
AT (1) ATE394103T1 (uk)
AU (2) AU2002214165B9 (uk)
BG (1) BG66009B1 (uk)
BR (1) BR0115511A (uk)
CA (1) CA2429263C (uk)
CY (1) CY1110428T1 (uk)
CZ (1) CZ301583B6 (uk)
DE (1) DE60133921D1 (uk)
DK (1) DK1339409T3 (uk)
EE (1) EE05507B1 (uk)
ES (1) ES2305118T3 (uk)
GB (1) GB0028429D0 (uk)
HK (1) HK1056691A1 (uk)
HU (1) HUP0301380A3 (uk)
IL (2) IL155919A0 (uk)
IS (1) IS6819A (uk)
MX (1) MXPA03004336A (uk)
MY (1) MY134902A (uk)
NO (1) NO326245B1 (uk)
NZ (1) NZ525754A (uk)
PL (1) PL365386A1 (uk)
PT (1) PT1339409E (uk)
RU (1) RU2294744C2 (uk)
SI (1) SI1339409T1 (uk)
SK (1) SK6212003A3 (uk)
TW (1) TWI238720B (uk)
UA (1) UA75614C2 (uk)
WO (1) WO2002041895A1 (uk)
ZA (1) ZA200303636B (uk)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
EA200501676A1 (ru) * 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005056534A1 (en) * 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
ZA200610167B (en) * 2004-05-26 2008-07-30 Kgksynergize Inc Functional foods comprising flavonoids and tocotrienols and methods thereof
JP2007508379A (ja) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
KR100945763B1 (ko) 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
CA2619576C (en) * 2005-08-16 2011-12-06 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
CN102089318B (zh) * 2008-07-08 2014-05-21 吉里德科学公司 Hiv抑制剂化合物的盐
CA3111317C (en) 2012-09-17 2023-08-29 F. Hoffmann-La Roche Ltd. Method of synthesizing thyroid hormone analogs and polymorphs thereof
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
AU2020283500A1 (en) 2019-05-27 2022-01-27 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
AU2022213405A1 (en) * 2021-02-01 2023-08-03 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate

Also Published As

Publication number Publication date
BG66009B1 (bg) 2010-10-29
NO20032292L (no) 2003-07-17
ES2305118T3 (es) 2008-11-01
HUP0301380A3 (en) 2007-03-28
DE60133921D1 (de) 2008-06-19
PL365386A1 (en) 2005-01-10
AR031766A1 (es) 2003-10-01
HUP0301380A2 (hu) 2003-10-28
SI1339409T1 (sl) 2008-08-31
UA75614C2 (uk) 2006-05-15
KR100815042B1 (ko) 2008-03-18
CA2429263A1 (en) 2002-05-30
WO2002041895A1 (en) 2002-05-30
BR0115511A (pt) 2003-12-30
JP2010031047A (ja) 2010-02-12
ZA200303636B (en) 2004-08-12
HK1056691A1 (en) 2004-02-27
BG107811A (bg) 2004-03-31
EP1339409B1 (en) 2008-05-07
EP1339409A1 (en) 2003-09-03
SK6212003A3 (en) 2003-11-04
NZ525754A (en) 2004-10-29
EE05507B1 (et) 2012-02-15
CY1110428T1 (el) 2015-04-29
US6858618B2 (en) 2005-02-22
AU1416502A (en) 2002-06-03
RU2294744C2 (ru) 2007-03-10
JP2004522714A (ja) 2004-07-29
IL155919A (en) 2009-09-01
CZ20031406A3 (cs) 2003-09-17
CN1268339C (zh) 2006-08-09
AU2002214165B2 (en) 2006-12-14
CN1630520A (zh) 2005-06-22
EE200300239A (et) 2003-08-15
JP5062940B2 (ja) 2012-10-31
IS6819A (is) 2003-05-19
TWI238720B (en) 2005-09-01
KR20030048479A (ko) 2003-06-19
US20040072852A1 (en) 2004-04-15
GB0028429D0 (en) 2001-01-10
CZ301583B6 (cs) 2010-04-21
IL155919A0 (en) 2003-12-23
MXPA03004336A (es) 2003-08-19
CA2429263C (en) 2009-03-17
NO326245B1 (no) 2008-10-27
AU2002214165B9 (en) 2013-07-04
PT1339409E (pt) 2008-07-07
MY134902A (en) 2007-12-31
ATE394103T1 (de) 2008-05-15
NO20032292D0 (no) 2003-05-21

Similar Documents

Publication Publication Date Title
DK1339409T3 (da) Anvendelse af rosuvastatin (ZD-4522) til behandling af heterozygot, familiær hypercholesterolæmi
NO20030795L (no) Kinazolinderivater
DE60018978D1 (de) Benutzerauthentifiezierung in medizinischen systemen
IS2940B (is) Mótefni gegn CD40
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
FI20010694A0 (fi) Implantti
NO20035573D0 (no) Kinazolinderivater
NO20041840L (no) Rosuvastatin ved predemente tilstander
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
DK1493442T3 (da) Reboxetin til behandling af perifer neuropati
ITTO20000776A0 (it) Ventilatore filtrante.
EE200300563A (et) Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim
FI20010477A0 (fi) Suodatinrakenne
ES1043922Y (es) Filtro nasal.
IT1307028B1 (it) Bendaggio.
DK1267849T3 (da) Begrænsning af genoptagelse af lægemiddelanvendelse
DE60206034D1 (de) Spritze
ES1050786Y (es) Monedero polivalente.
ITTO20010243V0 (it) Portamonete.
ITTO20010239U1 (it) Portamonete.
ITTO20010096V0 (it) Siringa.
ES1048887Y (es) Conjunto dispensador de infusiones de uso publico y/o privado.
ES1049553Y (es) Portamonedas
FIU990057U0 (fi) Tii
ITGE20010012V0 (it) Portamonete